TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11269754

Group type: EXPERIMENTAL
Intervention: Troponin T measurement
Number of subjects: 91

Group type: COMPARATOR
Intervention: Case control group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 91
Study: 9738131

Group type: EXPERIMENTAL
Intervention: Diet (4.19‐5.44 MJ or 1,200‐1,300 kcal/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Exercise (five 45‐min sessions at 78.5+/‐0.5% maximum heart rate)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise and Diet (ED)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 91
Study: 8066309

Group type: EXPERIMENTAL
Intervention: Verapamil (120-240 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10-20 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 31
Study: 3276167

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure reduction of 26.2 mmHg (standard error = 13.4)
Number of subjects: 10053

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure reduction of 10.0 mmHg (standard error = 5.3)
Number of subjects: 10053

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure reduction
Number of subjects: 10053

Group type: COMPARATOR
Intervention: Systolic blood pressure reduction
Number of subjects: 10053
Study: 31955237

Group type: EXPERIMENTAL
Intervention: Multi-radius posterior-stabilized mobile-bearing TKA
Number of subjects: 22
Study: 30056395

Group type: EXPERIMENTAL
Intervention: Intervention group A (primer letter/leaflet and a self‐referral letter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group B (primer letter/leaflet and a patient navigation call)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care; no input from GP practice)
Number of subjects: 0
Study: 27465872

Group type: EXPERIMENTAL
Intervention: Preoperative intracavitary irradiation (PII)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Radical hysterectomy (RH)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Overall comparison of groups
Number of subjects: 133
Study: 24909376

Group type: EXPERIMENTAL
Intervention: Audio-recorded information on compact disc (CD) during medical consultation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (standard information without audio recording)
Number of subjects: 130
Study: 21351188

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients (Tamoxifen and Exemestane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive test performance
Number of subjects: 0
Study: 20398941

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 397

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 397
Study: 18570193

Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual supportive psychotherapy
Number of subjects: 80
Study: 16116010

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 0.375% bupivacaine and 5 microg/mL epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no femoral nerve block)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with epidural analgesia
Number of subjects: 80
Study: 12364634

Group type: EXPERIMENTAL
Intervention: 5x300 mg 4162W94 (cohort 1 and 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5x100 mg 4162W94
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5x300 mg 4162W94
Number of subjects: 48
Study: 8763896

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 10703

Group type: EXPERIMENTAL
Intervention: Hypoxic cell sensitisers
Number of subjects: 10703

Group type: EXPERIMENTAL
Intervention: ARCON (accelerated radiotherapy, carbogen and nicotinamide)
Number of subjects: 10703

Group type: COMPARATOR
Intervention: Overall from meta-analysis
Number of subjects: 10703
Study: 2272136

Group type: EXPERIMENTAL
Intervention: Hexabrix (ionic low osmolar heparinized contrast media)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Isovue (nonionic low osmolar heparinized contrast media)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Hexabrix
Number of subjects: 500

Group type: COMPARATOR
Intervention: Isovue
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both Hexabrix and Isovue
Number of subjects: 500
Study: 7204712

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihistaminic classic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31125101

Group type: EXPERIMENTAL
Intervention: Regular group (app + accelerometer)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Plus group (app + accelerometer)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Combined regular and plus groups
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (accelerometer only)
Number of subjects: 210
Study: 28953776

Group type: EXPERIMENTAL
Intervention: Duloxetine + Acetylsalicylic Acid (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Escitalopram + Placebo
Number of subjects: 40
Study: 26364885

Group type: EXPERIMENTAL
Intervention: Patients with instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patients without instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall findings regarding the need for adaptive radiotherapy
Number of subjects: 20
Study: 23407470

Group type: EXPERIMENTAL
Intervention: Vaginal swab samples
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Other specimen types (endocervical swabs or urine)
Number of subjects: 4000
Study: 21247431

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg/kg intravenous bolus injection, followed by 1.5 mg/kg/h continuous intravenous infusion until 3 hours after cessation of CPB
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 28
Study: 19140906

Group type: EXPERIMENTAL
Intervention: Atrial rate‐adaptive pacing (AAIR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ventricular demand pacing (VVI)
Number of subjects: 10
Study: 17524595

Group type: EXPERIMENTAL
Intervention: Storytelling educational intervention (ST)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Numeric risk tool intervention (NR)
Number of subjects: 64
Study: 14760966

Group type: EXPERIMENTAL
Intervention: 20-year-old man
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 40-year-old man
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 60-year-old man
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Murder
Number of subjects: 95

Group type: COMPARATOR
Intervention: Theft
Number of subjects: 95
Study: 11522155

Group type: EXPERIMENTAL
Intervention: Sun protection education provided to aquatic staff at intervention pools.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Education on child injury prevention provided to aquatic staff at control pools.
Number of subjects: 220
Study: 9920070

Group type: EXPERIMENTAL
Intervention: 300 microg DSG orally daily and 100 mg T enanthate, i.m., weekly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 microg DSG and 50 mg T enanthate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 150 microg DSG and 100 mg T enanthate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DSG (300 or 150 microg daily) alone for the first 3 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Addition of T enanthate (50 and 100 mg weekly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DSG alone
Number of subjects: 24
Study: 7703390

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant erythropoietin (EPO)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 2641393

Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam administered sublingually
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (lactulose solution 66.7%)
Number of subjects: 40
Study: 19949

Group type: EXPERIMENTAL
Intervention: EHDP (20 mg kg‐1 day‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31390674

Group type: EXPERIMENTAL
Intervention: Personalized surgeon letter with surgical information, surgeon picture, and surgeon signature
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group received the same letter a month later
Number of subjects: 281
Study: 31967979

Group type: EXPERIMENTAL
Intervention: Photobiostimulation (PBS) after implant surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (simulated photobiostimulation) after implant surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (implant surgery only)
Number of subjects: 60
Study: 30146166

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D3 supplementation (100,000 IU)
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108
Study: 28595182

Group type: EXPERIMENTAL
Intervention: Dietary supplements containing 125 mg green tea, 25 mg capsaicin and 50 mg ginger extracts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25593284

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 45
Study: 23886127

Group type: EXPERIMENTAL
Intervention: Specially designed tobacco control program including anti-tobacco awareness classes, formation of anti-tobacco task forces, inter-school competitions, supplying IEC materials, and providing a handbook on tobacco control for school personnel.
Number of subjects: 4144
Study: 21817821

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) plus a statin
Number of subjects: 171

Group type: COMPARATOR
Intervention: Double dose of statin
Number of subjects: 171
Study: 19243207

Group type: EXPERIMENTAL
Intervention: Fed state (CER 30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fasted state (CER 30 mg)
Number of subjects: 16
Study: 16886114

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 106
Study: 14715180

Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 35 mg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 75 mg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 125 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 11710578

Group type: EXPERIMENTAL
Intervention: Diclofenac after oral administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac after rectal administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ibuprofen (internal standard)
Number of subjects: 10
Study: 9275110

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 448
Study: 7733220

Group type: EXPERIMENTAL
Intervention: School-based prevention program (modified classroom teacher practices, parent training, child social skills training)
Number of subjects: 0
Study: 2646315

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, subcutaneously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31829111

Group type: EXPERIMENTAL
Intervention: Cost prompt group (Picture Option Grid DA with cost discussion prompt)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Non-cost prompt groups (text‐only Option Grid DA and usual care)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cost prompt group
Number of subjects: 311

Group type: COMPARATOR
Intervention: Non-cost prompt groups
Number of subjects: 311
Study: 30325567

Group type: EXPERIMENTAL
Intervention: FTC/TAF 200/10 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg (treatment A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTC/TAF 200/25 mg alone (treatment C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRV/cobicistat (COBI) 800/150 mg (treatment B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTV and COBI boosting effects on TAF bioavailability
Number of subjects: 0
Study: 28609567

Group type: EXPERIMENTAL
Intervention: BI 1021958 (60 mg single dose)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: BI 1021958 (≥60 mg single doses)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: BI 1021958 (>40 mg multiple doses)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 25146413

Group type: EXPERIMENTAL
Intervention: Live delivery (LD)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Telemedicine delivery (TD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 118
Study: 24089234

Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section (IFS) performed, n=66
Number of subjects: 80

Group type: COMPARATOR
Intervention: No intraoperative frozen section (IFS) performed, n=14
Number of subjects: 80
Study: 21217530

Group type: EXPERIMENTAL
Intervention: Usual care and exercise (UC + EX) group performed a comprehensive prehabilitation program including resistance training using bands, flexibility, and step training at least 3 times per week for 4‐8 weeks before TKA.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care (UC) group maintained normal daily activities before TKA.
Number of subjects: 71
Study: 19949272

Group type: EXPERIMENTAL
Intervention: High-dose vitamin K (K(1) and K(2)) supplementation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose vitamin K(2) supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 17044661

Group type: EXPERIMENTAL
Intervention: Efonidipine (40 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nilvadipine (2 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 15149751

Group type: EXPERIMENTAL
Intervention: Permixon 320 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 124
Study: 11181371

Group type: EXPERIMENTAL
Intervention: Alpha(1)-acid glycoprotein (AAG) concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unbound or free amprenavir concentrations
Number of subjects: 0
Study: 9490088

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy protocols
Number of subjects: 4455
Study: 8282435

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 2959900

Group type: EXPERIMENTAL
Intervention: Nebulized fenoterol plus ipratropium bromide
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fenoterol plus steroids
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Aminophylline, IV, plus steroids and oral fenoterol
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nebulized normal saline solution
Number of subjects: 79
Study: 31880171

Group type: EXPERIMENTAL
Intervention: Dyadic planning (involving a non-smoking partner)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Individual planning
Number of subjects: 176
Study: 29969742

Group type: EXPERIMENTAL
Intervention: uTLIF with PMMA augmentation
Number of subjects: 50

Group type: COMPARATOR
Intervention: standard uTLIF
Number of subjects: 50
Study: 27838680

Group type: EXPERIMENTAL
Intervention: Alternative antimicrobial therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study: 26281326

Group type: EXPERIMENTAL
Intervention: Full face mask (Group F)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Helmet (Group H)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Group F and Group H)
Number of subjects: 50
Study: 24311880

Group type: EXPERIMENTAL
Intervention: Hot nature dietary intervention with co‐supplemented hemp seed and evening primrose oils
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Co‐supplemented hemp seed and evening primrose oils
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 100
Study: 21570642

Group type: EXPERIMENTAL
Intervention: 12 g casein hydrolysate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 6 g casein hydrolysate
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0 g casein hydrolysate (control)
Number of subjects: 13
Study: 17653855

Group type: EXPERIMENTAL
Intervention: Extended protocol (96 cores excised)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard protocol (24 cores obtained)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Extended protocol
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 266
Study: 16239622

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12968845

Group type: EXPERIMENTAL
Intervention: Silver-treated catheters
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control catheters
Number of subjects: 139
Study: 11101474

Group type: EXPERIMENTAL
Intervention: Fresh yogurt (500 g/d for 15 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heated yogurt (500 g/d for 15 days)
Number of subjects: 24
Study: 8704064

Group type: EXPERIMENTAL
Intervention: Intranasal administration of 20 IU AVP
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous administration of 1.5 IU AVP
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study: 1288668

Group type: EXPERIMENTAL
Intervention: Combination of physostigmine and deprenyl
Number of subjects: 16
Study: 6748070

Group type: EXPERIMENTAL
Intervention: Physical inactivity and smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactive men and smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age, Type A behavior pattern, blood pressure, serum cholesterol, serum high-density lipoprotein, and obesity
Number of subjects: 0
Study: 31644556

Group type: EXPERIMENTAL
Intervention: Hygiene and foot-care intervention (training in foot hygiene, skin care, bandaging, exercises, use of socks and shoes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hygiene and foot-care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (delayed intervention group)
Number of subjects: 0
Study: 29750632

Group type: EXPERIMENTAL
Intervention: R-CHOP (6 additional cycles)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Burkitt protocol (6 blocks)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: R-CHOP (4 additional cycles)
Number of subjects: 862

Group type: COMPARATOR
Intervention: R-CHOP with additional rituximab (4 additional cycles)
Number of subjects: 862
Study: 26908242

Group type: EXPERIMENTAL
Intervention: Early reversal of defunctioning ileostomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Late reversal of defunctioning ileostomy
Number of subjects: 26
Study: 25406780

Group type: EXPERIMENTAL
Intervention: Skin care protocol every 6 hours (gentle cleanser, moisturizer, skin protectant/barrier)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Skin care protocol every 12 hours (gentle cleanser, moisturizer, skin protectant/barrier)
Number of subjects: 99
Study: 23176104

Group type: EXPERIMENTAL
Intervention: Inpatient CR with resistance training and special balance training (5 d/wk)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation (CG)
Number of subjects: 173
Study: 20370378

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1 mg
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 2 mg
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 3 mg
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 18034867

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starches (HES) 130/0.4, 500 ml infusion over 15 minutes
Number of subjects: 24
Study: 15909194

Group type: EXPERIMENTAL
Intervention: 111In-DOTA-lanreotide (111In-DOTA-LAN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 111In-DOTA-D: Phe1-Tyr3-octreotide (111In-DOTA-TOC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 18F-fluorodeoxyglucose (FDG) PET
Number of subjects: 18
Study: 11843735

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 0
Study: 10512243

Group type: EXPERIMENTAL
Intervention: Barbiturate anesthesia during fasting (F+B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Barbiturate anesthesia during nonfasting (nonF+B)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fasting (F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonfasting (nonF)
Number of subjects: 8
Study: 8746602

Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril once a day between 7 p.m. and 11 p.m.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trough-to-peak ratio
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Median trough-to-peak ratio
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Surface ratio
Number of subjects: 66
Study: 2030195

Group type: EXPERIMENTAL
Intervention: Manual plus hotline
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 1813
Study: 7047579

Group type: EXPERIMENTAL
Intervention: Group C received placebo tablets and rinsed with folate MW twice daily for 1 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B received placebo MW and one 5 mg folate tablet daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group A received placebo mouthwash (MW) and placebo tablets
Number of subjects: 30